Steven Cohen Trevi Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $51 Billion
- Q3 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 941,929 shares of TRVI stock, worth $10.7 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
941,929
Previous 1,728,676
45.51%
Holding current value
$10.7 Million
Previous $9.46 Million
10.95%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
174Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...